Asia Pacific Neurodegenerative Disease Market Size, Share & Trends Analysis Report By Disease Indication (Multiple Sclerosis, Parkinson's Disease, Alzheimer's Disease, Others), By Drug Type (Immunomodulator, Vesicular Monoamine Transporter 2 (VMAT2), Others), By Routes of Administration (Oral, Intravenous (IV) delivery, Others) and By Country (China, Korea, Japan, India, Australia, Taiwan, South East Asia, Rest of Asia-Pacific) Forecasts, 2026-2034

Asia Pacific Neurodegenerative Disease Market Size

The worldwide neurodegenerative disease market size was valued at USD 12.08 Billion in 2025 and is projected to reach from USD 13.06 Billion in 2026 to USD 24.39 Billion by 2034, growing at a CAGR of 8.12% during the forecast period (2026-2034).

In most cases, neurodegenerative disorders are characterised by gradual nerve cell degeneration that can occur in a variety of locations across the body. Loss of memory and cognitive control are potential outcomes of a number of conditions, including Alzheimer's disease, Parkinson's disease, attention deficit hyperactivity disorder (ADHD), and amyotrophic lateral sclerosis (ALS).

Although there are very few diseases that can be cured, the pharmaceutical industry has developed a variety of treatments throughout the years that aim to alleviate the symptoms of neurodegenerative ailments.

Neurodegenerative disorders are a varied group of ailments defined by the gradual degradation of the function and structure of the central nervous system or peripheral nervous system. Neurodegenerative disorders, including Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, and Huntington's disease, have been rising globally. Thus, the growing burden of this condition is the key driver driving the market expansion, adding to it the expanding elderly population. According to NIH, nearly 1.2 million people in the United States will have Parkinson's disease by 2030. In the United States, it is the second most frequent neurodegenerative disorder.

Furthermore, according to Alzheimer's Disease International, more than 50 million adults with dementia globally in 2020. This number is anticipated to be more than double every two decades, reaching 82 million in 2030 and 152 million in 2050. Additionally, much of the increase will be in emerging countries. About 60% of persons with dementia reside in poor and middle-income nations, but by 2050, this will climb to 71% . The fastest rise in the senior population has happened in China, India, and South Asian and western Pacific countries. Thus, the growing burden of dementia is likely to enhance the market growth in the approaching years.

Asia Pacific Neurodegenerative Disease Market By Segment

By Disease Indication

The Asia Pacific neurodegenerative disease market is segmented by disease indication into multiple sclerosis, Parkinson's disease, Alzheimer's disease, and others. Multiple sclerosis requires continuous disease management and long-term therapeutic intervention, while Parkinson's disease is gaining greater attention with the increasing prevalence of age-related neurological disorders across the region. Alzheimer's disease represents another significant indication due to the expanding elderly population and growing awareness of cognitive health. Improvements in neurological diagnosis, specialist consultations, and disease monitoring are supporting earlier identification and treatment of these conditions across developed and emerging Asia Pacific markets.

The others category includes a wide range of neurodegenerative and neurological conditions that require specialized diagnosis and treatment. Increasing investment in neurological research, improved diagnostic technologies, and expanding access to specialist healthcare are supporting the identification of less common disorders. The overall disease indication segment is also benefiting from rising healthcare expenditure, greater patient awareness, and improvements in hospital infrastructure. However, variations in treatment affordability, reimbursement coverage, specialist availability, and healthcare accessibility continue to influence market development across individual countries.

Request Customizationto receive a tailored report.

By Drug Type

The Asia Pacific neurodegenerative disease market is classified by drug type into immunomodulator, vesicular monoamine transporter 2 (VMAT2), and others. Immunomodulators are used in therapies where regulating immune-system activity is relevant to disease management, while VMAT2-targeted treatments focus on pathways involved in neurotransmitter storage and regulation. Growing awareness of neurological disorders, improvements in diagnosis, and increasing access to specialized therapies are supporting demand for these drug categories. The availability of different treatment mechanisms also enables physicians to select therapies according to disease characteristics, patient response, and clinical requirements.

The others category encompasses drug therapies that operate through mechanisms outside immunomodulation and VMAT2 targeting. These treatments may address specific symptoms, neurological pathways, or disease-management requirements depending on the underlying condition. Pharmaceutical research into new molecular targets and therapeutic mechanisms is expanding the potential treatment landscape. Across Asia Pacific, drug adoption is influenced by regulatory approvals, treatment costs, reimbursement policies, physician awareness, medicine availability, and access to specialized neurological care. Improvements in healthcare infrastructure and pharmaceutical distribution are expected to support broader availability of advanced therapies.

By Routes of Administration

The Asia Pacific neurodegenerative disease market is segmented by routes of administration into oral, intravenous (IV) delivery, and others. Oral administration remains an important route because tablets and capsules offer convenience for patients requiring long-term treatment and can generally be incorporated into outpatient care. This approach can reduce dependence on frequent clinical visits and simplify treatment routines for patients and caregivers. Intravenous (IV) delivery is used when medicines require direct bloodstream administration, controlled dosing, or supervision by healthcare professionals. Expansion of hospitals, specialty clinics, and neurological treatment centers is improving access to infusion-based therapies across the region.

The others category covers alternative administration approaches that may be selected when oral or IV delivery is unsuitable or when a specific formulation provides therapeutic advantages. Advances in drug-delivery technologies are encouraging the development of formulations designed to improve absorption, maintain consistent drug exposure, and enhance treatment convenience. The selection of an administration route depends on the drug's characteristics, patient requirements, disease severity, and clinical considerations. Across Asia Pacific, adoption of different delivery methods will be influenced by healthcare infrastructure, treatment affordability, regulatory requirements, specialist availability, and the introduction of innovative neurological therapies.

Speak to an Analystto discuss market opportunities.

Regional Analysis

The incidence of cerebrovascular and neurodegenerative illnesses in Asia is the highest it is anywhere in the globe, out of more than 600 different neurological conditions.

Ischemic strokes and transient ischemic attacks (also known as TIAs) are two types of cerebrovascular illnesses that are far more prevalent in Asia, notably in South and certain areas of Southeast Asia, than they are in Europe or North America. In India and Indonesia, stroke is the main cause of death, accounting for between one-third and one-fifth of all premature deaths in those nations respectively. In the United States, stroke is the third greatest cause of death overall. A research that was conducted in 2015 by the Indian Academy of Neurology found that there are more than 1.8 million people in the nation who are coping with the aftereffects of having a stroke. This pattern can be explained in large part by the prevalence of risk factors in the region, which include hypertension, high cholesterol, diabetes, and cigarette smoking. As a result of an increase in the population's awareness of the need of maintaining a healthy lifestyle, the incidence of cerebrovascular disorders has decreased over the past decade in high-income nations such as Japan, Korea, Taiwan, and Singapore.

As a result of the rapidly increasing elderly population in many Asian nations, neurodegenerative illnesses have been on an upward trend for some time. At the moment, more than one-quarter of the population in Japan is over the age of 65, while other nations such as Korea, China, Taiwan, and Singapore are all predicted to suffer accelerated ageing in the near future. A research that was published in 2016 in the Journal of Internal Medicine found that Alzheimer's Disease (AD) is the most frequent form of neurodegenerative dementia in Asia, accounting for more than 60% of all cases. The number of people living with Alzheimer's disease is projected to be 7 million in China, 4 million in India, and 1.5 million in Japan. Although the prevalence of Parkinson's Illness (PD) in Asia is slightly lower than that in Europe or North America, it is still the second most frequent kind of neurodegenerative disease in the region.

There has been a significant drop in the prevalence of neuroinfectious illnesses throughout Asia; nonetheless, diseases such as paragonimiasis and Japanese encephalitis can still be found in rural and warmer areas. Although the number of people diagnosed with brain and central nervous system tumours is still relatively low when compared to other types of cancer, the incidence of these diseases has been progressively rising.

List of Key and Emerging Players in Asia Pacific Neurodegenerative Disease Market